Suven Pharma tanks 10% on poor Q3 show, sharp margin erosion
Suven Pharma reported a sharp decline in its net profit, revenue and profitability in Q3.
Stay updated with breaking news from Uzzing Stocks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Suven Pharma reported a sharp decline in its net profit, revenue and profitability in Q3.
If approved, this will be the second buyback by the company. The first was in June 2022
Tata Consultancy Services Ltd surged over 9 percent so far in 2024 while Tata Motors Ltd advanced over 20 percent. Tata Power jumped 18 percent while Indian Hotels gained 16 percent
Wipro has the highest number of 'sell' calls from brokerages, at 22. It has 10 'buy' and 12 'hold' calls. Tech Mahindra follows with 17 'sell', 14 'buy', and 12 'hold' ratings. Next is LTIMindtree, which has 17 sells, 13 buys, and 12 holds.
For Abbott India, strong demand in the quarter offset the adverse impact of pricing cap on certain drugs